



LJMU Research Online

Harland, E, Alhusban, D, Abdoubaki, R, Marfing, D, Simm, A, McCloskey, AP, Ehtezazi, T and Ross, K

A novel peptide for microRNA delivery to medulloblastoma cells

<http://researchonline.ljmu.ac.uk/id/eprint/23688/>

Article

Citation (please note it is advisable to refer to the publisher's version if you intend to cite from this work)


Harland, E, Alhusban, D, Abdoubaki, R, Marfing, D, Simm, A, McCloskey, AP, Ehtezazi, T and Ross, K (2023) A novel peptide for microRNA delivery to medulloblastoma cells. *Biomolecular Research Reports*, 1 (1). pp. 1-11.

LJMU has developed **LJMU Research Online** for users to access the research output of the University more effectively. Copyright © and Moral Rights for the papers on this site are retained by the individual authors and/or other copyright owners. Users may download and/or print one copy of any article(s) in LJMU Research Online to facilitate their private study or for non-commercial research. You may not engage in further distribution of the material or use it for any profit-making activities or any commercial gain.

The version presented here may differ from the published version or from the version of the record. Please see the repository URL above for details on accessing the published version and note that access may require a subscription.

For more information please contact researchonline@ljmu.ac.uk

<http://researchonline.ljmu.ac.uk/>



Biomolecular Research Reports

**December 2023
Volume 1 Issue 1**

Liverpool John Moores University



A novel peptide for microRNA delivery to medulloblastoma cells

Corresponding author: Kehinde Ross
School of Pharmacy and Biomolecular Sciences
Liverpool John Moores University
Liverpool
L3 3AF
Email: o.k.ross@ljmu.ac.uk
ORCID ID: orcid.org/0000-0003-0252-1152

Ellie Harland¹, Dima Alhusban¹, Roush Abdoubaki¹, Dallas Marfing¹, Alan Simm¹, Alice McCloskey^{1,2}, Touraj Ehtezazi^{1,2}, Kehinde Ross^{1,2}

¹School of Pharmacy and Biomolecular Sciences, Liverpool John Moores University, Liverpool, United Kingdom.

²Institute for Health Research, Liverpool John Moores University, Liverpool, United Kingdom.

Medulloblastoma is a paediatric brain cancer categorised into various subtypes that have differing prognostic outcomes for patients. As with other cancers, microRNAs have been implicated in medulloblastoma pathogenesis and the loss of specific miRNAs appears to contribute to the disease. There is therefore an urgent need to develop miRNA-replacement therapies for medulloblastoma. However, methods for targeted delivery of small RNAs to medulloblastoma cells have not been fully established. As a step towards tackling this challenge, we have developed self-assembling peptide nanoparticles for small RNA delivery to medulloblastoma cells. We generated an amphiphilic peptide, TY-28, using solid-phase peptide synthesis and combined TY-28 with miR-124-3p. Analysis of the resulting complexes by electron microscopy and dynamic light scattering confirmed the formation of nanoparticles. The ability of the NPs to penetrate cells was monitored by labelling the miRNA with a fluorescent dye. The NP:miRNA complexes were readily internalised by group 3 medulloblastoma cells, and the accumulation of the complexes increased over time. Levels of uptake were 6-fold higher at 24 hours compared to 4 hours in serum-free medium. The uptake of the NPs complexes by the cells did not differ in the presence and absence of serum, suggesting the presence of serum did not affect complex stability. Our findings point to the translational potential of self-assembled NPs to delivery miRNA mimics to medulloblastoma cells.

Key words: Medulloblastoma; MicroRNA; Peptides; Nanoparticles

INTRODUCTION

Primary tumours of the central nervous system (CNS) are the most common cancer sites in children [1]. Medulloblastoma (MB) stands out among these cancers as it accounts for ~10% of malignant brain tumours in children from birth up to 14 years old [2]. Molecular profiling has enabled four main medulloblastoma subgroups to be differentiated on the basis of transcriptional and epigenetic landscapes: Wingless (WNT)-activated, Sonic Hedgehog (SHH)-activated, Group 3 and Group 4 [3-6]. Further disease heterogeneity has also been recognised, with four subtypes of SHH and eight subtypes (I-VIII) spanning Group 3 and 4 [7, 8]. Treatment outcomes depend on the disease subtype and highly aggressive tumours metastasise through cerebrospinal fluid to other regions of the CNS, ultimately leading to mortality [9].

Mature miRNAs are small ~22 nucleotide non-coding RNAs that repress gene expression upon binding to the 3' untranslated region (UTR) of target mRNA transcripts [10]. Importantly, mature miRNAs are structurally and functionally similar to small-interfering RNA (siRNA) and both types of small RNA are loaded into Argonaute (AGO) proteins to form the RNA-induced silencing complex (RISC) [11]. The miRNA/siRNA guides the RISC to target mRNA transcripts in order to silence target genes through AGO-dependent mechanisms [12].

These miRNAs are only partially complementary to their targets, and a given miRNA can downregulate hundreds of targets, first through acute translational repression but subsequently by steady-state mRNA destabilisation [13]. Changes in miRNA expression are associated with the hallmarks of cancer and therefore represent important targets for the development of nucleic acid therapies [14-17].

Early studies revealed that the expression of miR-124-3p was significantly reduced in medulloblastoma cells compared to normal cerebellum, with overexpression of miR-124-3p inhibiting the proliferation of medulloblastoma cells in vitro and in a xenograft mouse model of the disease [18-21]. However, mechanisms for targeted effective delivery of miR-124-3p mimics to patient cells have not been established and no clinical trials for miR-124-3p replacement therapy in MB have been registered on the <https://clinicaltrials.gov/> database.

Self-assembling peptide nanoparticles (NPs) have emerged as novel drug delivery systems for cancer [22, 23]. Multiple efforts have been made to deploy such peptide-based drug delivery systems (DDS) for delivery of miRNA [24-29], miRNA inhibitors [30] and siRNA [25, 31-43]. However, the potential of self-assembling peptide NPs for miRNA/siRNA delivery to medulloblastoma cells has received little attention.

Recently, we introduced amphiphilic cell penetrating peptides (CPP) comprised of a peptide inhibitor of matrix metalloproteinase 9 (MMP-9) and an N-terminal cholesterol moiety to drive self-assembly in aqueous media [44, 45]. The peptides, with and without encapsulation of siRNA cargo, traversed an in vitro model of the blood-brain barrier (BBB) model [44, 45]. We re-engineered the peptides using hydrophobic amino acids to generate TY-28 (sequence GGGWGPIACDIFTNSRGKRA) with a view to simplifying the production of peptide NPs by obviating the incorporation of cholesterol.

In this study, we have evaluated the translational potential of TY-28-based NPs by investigating their ability to deliver miRNA into medulloblastoma cells. We generated and characterised self-assembled TY-28 NPs loaded with a miR-124-3p mimic and used HD-MB03 group 3 medulloblastoma cells as a disease model. The miRNA-loaded NPs were characterised using electron microscopy and dynamic light scattering. Uptake of the miRNA-loaded NPs by medulloblastoma cells was tested in the presence and absence of serum. Our findings suggest that TY-28 associates with miR-124-3p mimic to form NPs that are readily internalised by medulloblastoma cells and lay the foundation for further work to develop miRNA-based nucleic acid therapies for childhood brain cancer.

MATERIAL AND METHODS

Peptide Synthesis

Fmoc N-protected amino acids, Rink Amide ProTide resin and Oxyma Pure™ were purchased from CEM Microwave Technology Ltd, dimethylformamide (DMF) from Acros Organics and other reagents were from Merck. Solid-phase peptide synthesis (SPPS) was performed on a CEM Liberty Blue® automated microwave peptide synthesizer. Briefly, 14 g of Oxyma in 100 mL of dimethylformamide (DMF) was used as the activator base and 15 mL of N,N'-diisopropylcarbodiimide (DIC) in 100 mL of DMF as the activator. Wash steps were performed with DMF and deprotection with 20% piperidine in DMF, then 179 mg of Rink amide resin was added to the reaction vessel. Upon completion of the peptide synthesis reaction, the resin was filtered using a 10 mL syringe and a silicone-based porous bed while washing with dichloromethane. Diethyl ether was added to the syringe and the resin shrunk by vacuum suction. A cleavage cocktail of 400 µL triisopropyl silane (TIPS), 400 µL distilled water and 3.2 mL trifluoroacetic acid (TFA) was used to detach the peptide from the resin, rotating the syringe for 3-4 hours at room temperature. The peptide was precipitated in cold diethyl ether and centrifuged (Hermle Z400 centrifuge) at 3500 rpm for 5 minutes. The previous step was repeated twice to remove impurities and residues of TIPS and TFA. The diethyl ether was evaporated in a fridge at 4°C before dissolving the pellet in 7.5 mL pyrogen-free water by sonication in an ultrasonic cleaning tank. Afterwards, the solution was split into seven 2 mL vials and freeze-dried overnight at -60°C.

Dynamic Light Scattering (DLS)

A Malvern Zetasizer Nano ZS® (Malvern, Worcestershire, UK) was employed to quantify the zeta potential, polydispersity index (Pdl) and particle size using the dynamic light scattering (DLS) method. For analysis of particle size and Pdl, a 4 clear-sided cuvette (DTS0012) from Malvern was used. TY-28 powder (12 mg) was dispersed in 3 mL of DNase/RNase-free water, and the diameters of the peptide NPs were measured after a delay of two minutes.

Transmission Electron Microscopy (TEM)

TY-28 NPs were visualized and characterized with morphological descriptions using electron microscopy as previously reported [44, 45]. Copper grids with carbon film were employed and a droplet of TY-28 NPs (3 mg/mL) in DNase/RNase-free water was applied to the grid and air dried in a fume hood. The NPs were observed at a 100 kV accelerating voltage on a FEI Morgagni 268D transmission electron microscope (Oxford Instruments).

Cell Culture and Transfection for Cell Imaging

HD-MB03 medulloblastoma cells were a kind gift from Gianpiero Di Leva (Keele University, United Kingdom) and have been described in detail elsewhere [46]. Cells were maintained in Roswell Park Memorial Institute (RPMI) medium supplemented with foetal calf serum and antibiotics. For NP uptake studies, cells were seeded at 30,000 cells per well of an 8-well chambered coverglass (Nunc™ Lab-Tek™ II Chamber Slide™ System, ThermoFisher) the day prior to transfection. Fluorescently labelled miR-124-3p was obtained from Horizon Discovery (Cambridge, UK), with TAMRA attached to the 3' end of the passenger strand. Briefly, 7.5 µL of fluorescent miRNA (20 µM stock) was added to 100 µL nuclease free water in a 1.5 mL microcentrifuge tube. Separately, 3 mg TY-28 peptide was dissolved in 650 µL nuclease free water. The peptide was then added dropwise to the miRNA solution, and mixed gently by pipetting up and down 4 times, giving a final miRNA concentration of 200 nM and final peptide final concentration of 4 mg/mL. The culture medium on the wells was replaced with 180 µL of complete or serum-free medium, then 20 µL of the peptide:miRNA mixture added to give a final miRNA concentration of 20 nM (4 pmol per well).

Confocal Microscopy and Image Analysis

Cells were fixed in ice-cold methanol for 10 min at -20°C and mounted in Fluoromount G with DAPI for nuclear counter-staining. Cells were visualised on a Zeiss LSM 900 confocal microscopy using an excitation wavelength of 561 nm and an emission window of 545-700 nm for TAMRA, while an excitation wavelength of 405 nm and an emission window of 400-535 nm was used for DAPI. Fluorescence was quantified as integrated densities in ImageJ [47]. The corrected total cell fluorescence (CTCF) was calculated using the following formula: $CTCF = \text{Integrated density} - (\text{area of selected cell} \times \text{mean fluorescence of background readings})$.

Statistical Analysis

Analysis of variance (ANOVA) and Student's t tests were performed where indicated, using Microsoft Excel. P values <0.05 were considered significant.

RESULTS AND DISCUSSION

Characterisation of miR-124-3-loaded peptide nanoparticles

To gain insight into the ultrastructure of NPs formed upon combining TY-28 peptide with miRNA, samples were analysed by transmission electron microscopy. Visual assessment of the electron micrographs indicated the NPs were largely ovoid in shape, but the sizes appeared to vary considerably (Fig. 1A). Consistent with this, a broad size distribution was observed by dynamic light scattering in the range of 20-300 nm, with peaks of 38.9 nm and 136.6 nm (Fig 1B). Typical ghost-peaks are also visible in Fig. 1B, which are not related to particle size. In addition, the polydispersity index of the NPs was 0.843, which reflects a degree of heterogeneity given that homogenous NPs are expected to give PDI of <0.2 [48]. The zeta potential of the NPs was 0.963 mV, reflecting a positive surface charge to facilitate electrostatic interactions with the negatively charged miRNA. Together, these findings indicate that the combination of




Figure 1. Structural properties of peptide-miRNA complexes (A) Transmission electron micrograph of TY-28 peptide NPs loaded with miR-124-3p. Scale bar = 2000 nm. (B) Representative size distribution of the miR-124-3p-loaded TY-28 peptide NPs assessed by dynamic light scattering. The main particle size is in the range of 20-300 nm. The artefact peaks (ghost peaks) are also visible at both extreme ends of the x-axis, which do not represent particles.

TY-28 and miRNA results in formation of NPs in a size range suitable for drug delivery to the brain [49].

Uptake of miR-124-3p-loaded peptide nanoparticles

For evaluation of the ability of TY-28 to deliver miRNA into medulloblastoma cells, fluorescently labelled miR-124-3p was complexed with TY-28 and the complexes applied to cells in the presence or absence of serum. Fluorescence was observed distributed uniformly throughout the cytoplasm and nucleus of the cells after 24 h (Fig. 2A). Levels of fluorescence appeared similar regardless of whether serum was maintained in or excluded from the culture media (Fig. 2A). However, quantification of the fluorescence indicated a slight reduction in uptake by cells maintained in complete media compared to those maintained in serum-free medium during the transfection (Fig.2B). Together, these observations suggest that the ability of the peptide-NPs




Figure 2. Peptide nanoparticle-mediated uptake of miRNA by medulloblastoma cells. Representative image of HD-MB03 cells transfected with fluorescently labelled miR-124-3p using TY-28 peptide NPs. Upper panel, cells were maintained in complete medium during transfection. Lower panel, cells were maintained in serum-free medium during transfection. Nuclei were stained with DAPI. Scale bar = 10 μ m. (B) Comparison of fluorescence intensities of cells transfected with fluorescently labelled miR-124-3p in the presence (blue bars) and absence (dark bars) of serum. The cells were fixed after 24 h and the corrected fluorescence intensity determined from $n = 30$ cells from 5 fields of view in each case. *, $p < 0.05$

to be internalised was not affected by the presence of serum. Importantly, no uptake was observed in cells incubated with the labelled miR-123-3p alone (data not shown). This indicates that the miRNA is not internalised in the absence of the peptide NP.

To determine whether TY-28:miRNA complexes were equally accessible to other cell types, uptake by epidermal keratinocytes was also examined. Few fluorescent cells were observed after exposing HaCaT keratinocytes to TY28:miR-184 complexes for 24 h, and the NPs that were taken up appeared to form a single large cytosolic aggregate or diffuse complexes that were confined to different parts of cytoplasm (data not shown). This suggests that TY-28 NPs are not indiscriminately internalised in a non-specific manner that enables penetration of any cell type. This is an important consideration in terms of the safety of TY-28 NPs, but systematic evaluation of the safety of TY-28 NPs on all major organs and tissues is required to support clinical translation.

Kinetics of uptake

Early studies suggested the uptake of CPPs peaks between 1 and 3 hours after application to cells [50]. We therefore examined the uptake of the peptide NPs after short exposure to the cells. Limited uptake was observed at 0.5–4 h application, and there was no statistically significant difference in fluorescence between cells in complete media and those in serum-free media (Fig 3A). Corrected fluorescence intensities ranged from 3.6 to 5.8 in complete media and 2.8 to 5.2 to under serum-free conditions (Fig. 3A). This contrasts with the fluorescence intensities of 27 and 33 in complete and serum-free media, respectively, after 24 h of incubation with the peptide NP complexes (Fig 2B). Thus comparison of fluorescence intensities at 4 and 24 h indicated ~6-fold higher accumulation of TY-28:miR-124-3p complexes in HD-MB03 cells maintained in complete and serum free medium, respectively (Fig. 3B). These findings suggest the internalisation of the peptide:miRNA complexes was time-dependent, with substantially higher levels of the complexes by 24 h compared to 4 hours or less. In this work, we focussed on miRNA-loaded TY-28 uptake. However, we cannot rule out the possibility that accumulation kinetics of TY-28:miRNA complexes may differ from those of unloaded TY-28 nanoparticles. Experiments are thus required using fluorescently labelled TY-28, generated either using fluorescently labelled natural amino acids or fluorescent amino acid analogues, to determine how the uptake dynamics compares to those reported here for the miRNA-loaded TY-28. The latter approach may obviate some of the concerns that have been raised about the effects of fluorescent dyes on the behaviour of CPPs [51]

Together these findings indicate that TY-28-based peptide NP can deliver miRNA into medulloblastoma cells, and the NP:miRNA complexes accumulate throughout the cell in a diffuse pattern. We found that a 72-h treatment with 20 nM miRNA reduced cell viability to 20% compared to untreated cells when miR-124-




Figure 3. Temporal analysis of peptide-miR-124-3p uptake. (A) Cells transfected with TY-28 peptide NPs loaded with fluorescently labelled miR-124-3p in the presence (blue bars) or absence (dark bars) of serum were fixed at the indicated time points. The corrected fluorescence intensity was determined from $n = 30$ cells from 5 fields of view in each case. (B) The corrected fluorescence intensities at 24 h from Fig. 2B were normalised to those of the 4 h time point from Fig. 3A above. *** $p < 0.001$

3p was delivered using TY-28. However, the effects of miR-124-3p were not specific, as a similar decrease in cell viability was observed using a non-targeting control oligonucleotide. This observation was not limited to TY-28 given that no difference in viability was detected when cells were transfected with miR-124-3p or control oligonucleotide using a commercial transfection reagent (nanocin RNA, from Tecrea Ltd). Thus, the ability of TY-28 to promote accumulation of miR-124-3p in MB03 cells does not appear sufficient to evoke miRNA-specific effects under our experimental conditions. Notably, studies from the Khvorova group suggest intracellular accumulation of exogenous small RNA (siRNA in their studies) does not of itself adequately reflect efficacy [52]. Hence, there may be factors linked to intracellular localisation, trafficking and endosomal escape, or lack thereof, that preclude detection of differential miR-124-3p activity compared to non-targeting oligonucleotides under our conditions.

Overall, the presence of serum in the culture medium had limited effects on the uptake of miRNA-loaded TY-

28 nanoparticles. Temporal analysis suggest somewhat slow uptake kinetics that seems limited internalisation over short time frames (<4 hours) given way to substantial accumulation within the medulloblastoma cells over 24 h. One limitation of the study, however, is that only HD-MB03 medulloblastoma cells have been examined. Additional studies are required on other medulloblastoma cells to establish the broad translational potential of TY-28 NPs for delivery of miRNA and other small RNAs in medulloblastoma.

The study also lacks functional evaluation of the miR-124-3p loaded NPs. Our initial tests suggested the TY28:miR-124-3p complexes were as effective as a commercial agent at reducing the viability of HD-MB03 cells. However, at the concentration used, the non-targeting control miRNA mimic reduced viability to the same extent. Hence further studies are required to establish the potential of miR-124-3p-loaded peptide NPs to inhibit the viability of medulloblastoma cells.

In conclusion, we show for the first time to our knowledge effective internalisation of miRNA-loaded peptide NPs by medulloblastoma cells. We envisage the application of these peptide NPs in the context of miRNA-replacement therapy for medulloblastoma. Further testing of the miR-124-3p loaded NPs in preclinical models of medulloblastoma will assist in finding its ultimate potential as a medulloblastoma therapy for the 21st century.

CONFLICT OF INTEREST

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

AUTHOR CONTRIBUTIONS

FUNDING

ACKNOWLEDGMENTS

We thank Paul Gibbons for help with electron microscopy and Peter Hamlett for technical support. E.H. was supported by a School of Pharmacy and Biomolecular Sciences Summer Research Bursary at Liverpool John Moores University.

REFERENCES

- Ostrom, Q. T., Cioffi, G., Gittleman, H., Patil, N., Waite, K., Kruchko, C. and Barnholtz-Sloan, J. S. (2019) CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2012-2016. *Neuro Oncol.* 21, v1-v100. <https://doi.org/10.1093/neuonc/noz150>
- Millard, N. E. and De Braganca, K. C. (2016) Medulloblastoma. *J Child Neurol.* 31, 1341-1353. <https://doi.org/10.1177/0883073815600866>
- Taylor, M. D., Northcott, P. A., Korshunov, A., Remke, M., Cho, Y. J., Clifford, S. C., Eberhart, C. G., Parsons, D. W., Rutkowski, S., Gajjar, A., Ellison, D. W., Lichter, P., Gilbertson, R. J., Pomeroy, S. L., Kool, M. and Pfister, S. M. (2012) Molecular subgroups of medulloblastoma: the current consensus. *Acta Neuropathol.* 123, 465-472. <https://doi.org/10.1007/s00401-011-0922-z>
- Northcott, P. A., Jones, D. T., Kool, M., Robinson, G. W., Gilbertson, R. J., Cho, Y. J., Pomeroy, S. L., Korshunov, A., Lichter, P., Taylor, M. D. and Pfister, S. M. (2012) Medulloblastomics: the end of the beginning. *Nature reviews.* 12, 818-834. <https://doi.org/10.1038/nrc3410>
- Northcott, P. A., Buchhalter, I., Morrissy, A. S., Hovestadt, V., Weischenfeldt, J., Ehrenberger, T., Grobner, S., Segura-Wang, M., Zichner, T., Rudneva, V. A., Warnatz, H. J., Sidiropoulos, N., Phillips, A. H., Schumacher, S., Kleinheinz, K., Waszak, S. M., Erkek, S., Jones, D. T. W., Worst, B. C., Kool, M., Zapatka, M., Jager, N., Chavez, L., Hutter, B., Bieg, M., Paramasivam, N., Heinold, M., Gu, Z., Ishaque, N., Jager-Schmidt, C., Imbusch, C. D., Jugold, A., Hubschmann, D., Risch, T., Amstislavskiy, V., Gonzalez, F. G. R., Weber, U. D., Wolf, S., Robinson, G. W., Zhou, X., Wu, G., Finkelstein, D., Liu, Y., Cavalli, F. M. G., Luu, B., Ramaswamy, V., Wu, X., Koster, J., Ryzhova, M., Cho, Y. J., Pomeroy, S. L., Herold-Mende, C., Schuhmann, M., Ebinger, M., Liau, L. M., Mora, J., McLendon, R. E., Jabado, N., Kumabe, T., Chuah, E., Ma, Y., Moore, R. A., Mungall, A. J., Mungall, K. L., Thiessen, N., Tse, K., Wong, T., Jones, S. J. M., Witt, O., Milde, T., Von Deimling, A., Capper, D., Korshunov, A., Yaspo, M. L., Kriwacki, R., Gajjar, A., Zhang, J., Beroukhim, R., Fraenkel, E., Korbel, J. O., Brors, B., Schlesner, M., Eils, R., Marra, M. A., Pfister, S. M., Taylor, M. D. and Lichter, P. (2017) The whole-genome landscape of medulloblastoma subtypes. *Nature.* 547, 311-317. <https://doi.org/10.1038/nature22973>
- Louis, D. N., Perry, A., Reifenberger, G., von Deimling, A., Figarella-Branger, D., Cavenee, W. K., Ohgaki, H., Wiestler, O. D., Kleihues, P. and Ellison, D. W. (2016) The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary. *Acta Neuropathol.* 131, 803-820. <https://doi.org/10.1007/s00401-016-1545-1>
- Sharma, T., Schwalbe, E. C., Williamson, D., Sill, M., Hovestadt, V., Mynarek, M., Rutkowski, S., Robinson, G. W., Gajjar, A., Cavalli, F., Ramaswamy, V., Taylor, M. D., Lindsey, J. C., Hill, R. M., Jager, N., Korshunov, A., Hicks, D., Bailey, S., Kool, M., Chavez, L., Northcott, P. A., Pfister, S. M. and Clifford, S. C. (2019) Second-generation molecular subgrouping of medulloblastoma: an international meta-analysis of Group 3 and Group 4 subtypes. *Acta Neuropathol.* 138, 309-326. <https://doi.org/10.1007/s00401-019-02020-0>
- Cavalli, F. M. G., Remke, M., Rampasek, L., Peacock, J., Shih, D. J. H., Luu, B., Garzia, L., Torchia, J., Nor, C., Morrissy, A. S., Agnihotri, S., Thompson, Y. Y., Kuzan-Fischer, C. M., Farooq,

- H., Isaev, K., Daniels, C., Cho, B. K., Kim, S. K., Wang, K. C., Lee, J. Y., Grajkowska, W. A., Perek-Polnik, M., Vasiljevic, A., Faure-Contier, C., Jouvet, A., Giannini, C., Nageswara Rao, A. A., Li, K. K. W., Ng, H. K., Eberhart, C. G., Pollack, I. F., Hamilton, R. L., Gillespie, G. Y., Olson, J. M., Leary, S., Weiss, W. A., Lach, B., Chambless, L. B., Thompson, R. C., Cooper, M. K., Vibhakar, R., Hauser, P., van Veelen, M. C., Kros, J. M., French, P. J., Ra, Y. S., Kumabe, T., Lopez-Aguilar, E., Zitterbart, K., Sterba, J., Finocchiaro, G., Massimino, M., Van Meir, E. G., Osuka, S., Shofuda, T., Klekner, A., Zollo, M., Leonard, J. R., Rubin, J. B., Jabado, N., Albrecht, S., Mora, J., Van Meter, T. E., Jung, S., Moore, A. S., Hallahan, A. R., Chan, J. A., Tirapelli, D. P. C., Carlotti, C. G., Fouladi, M., Pimentel, J., Faria, C. C., Saad, A. G., Massimi, L., Liau, L. M., Wheeler, H., Nakamura, H., Elbabaa, S. K., Perezpena-Diazconti, M., Chico Ponce de Leon, F., Robinson, S., Zapotocky, M., Lassaletta, A., Huang, A., Hawkins, C. E., Tabori, U., Bouffet, E., Bartels, U., Dirks, P. B., Rutka, J. T., Bader, G. D., Reimand, J., Goldenberg, A., Ramaswamy, V. and Taylor, M. D. (2017) Intertumoral Heterogeneity within Medulloblastoma Subgroups. *Cancer cell*. 31, 737-754 e736. <https://doi.org/10.1016/j.ccell.2017.05.005>
9. Fults, D. W., Taylor, M. D. and Garzia, L. (2019) Leptomeningeal dissemination: a sinister pattern of medulloblastoma growth. *J Neurosurg Pediatr*, 1-9. <https://doi.org/10.3171/2018.11.PEDS18506>
10. O'Brien, J., Hayder, H., Zayed, Y. and Peng, C. (2018) Overview of MicroRNA Biogenesis, Mechanisms of Actions, and Circulation. *Front Endocrinol (Lausanne)*. 9, 402. <https://doi.org/10.3389/fendo.2018.00402>
11. Frederick, P. M. and Simard, M. J. (2022) Regulation and different functions of the animal microRNA-induced silencing complex. *Wiley interdisciplinary reviews. RNA*. 13, e1701. <https://doi.org/10.1002/wrna.1701>
12. Muller, M., Fazi, F. and Ciaudo, C. (2019) Argonaute Proteins: From Structure to Function in Development and Pathological Cell Fate Determination. *Front Cell Dev Biol*. 7, 360. <https://doi.org/10.3389/fcell.2019.00360>
13. Eichhorn, S. W., Guo, H., McGeary, S. E., Rodriguez-Mias, R. A., Shin, C., Baek, D., Hsu, S. H., Ghoshal, K., Villen, J. and Bartel, D. P. (2014) mRNA Destabilization Is the Dominant Effect of Mammalian MicroRNAs by the Time Substantial Repression Ensues. *Mol Cell*. 56, 104-115. <https://doi.org/10.1016/j.molcel.2014.08.028>
14. Shah, V. and Shah, J. (2020) Recent trends in targeting miRNAs for cancer therapy. *J Pharm Pharmacol*. 72, 1732-1749. <https://doi.org/10.1111/jphp.13351>
15. Si, W., Shen, J., Zheng, H. and Fan, W. (2019) The role and mechanisms of action of microRNAs in cancer drug resistance. *Clinical epigenetics*. 11, 25. <https://doi.org/10.1186/s13148-018-0587-8>
16. Crooke, S. T., Baker, B. F., Crooke, R. M. and Liang, X. H. (2021) Antisense technology: an overview and prospectus. *Nature reviews*. 20, 427-453. <https://doi.org/10.1038/s41573-021-00162-z>
17. Roberts, T. C., Langer, R. and Wood, M. J. A. (2020) Advances in oligonucleotide drug delivery. *Nature reviews*. 19, 673-694. <https://doi.org/10.1038/s41573-020-0075-7>
18. Pierson, J., Hostager, B., Fan, R. and Vibhakar, R. (2008) Regulation of cyclin dependent kinase 6 by microRNA 124 in medulloblastoma. *Journal of neuro-oncology*. 90, 1-7. <https://doi.org/10.1007/s11060-008-9624-3>
19. Li, K. K., Pang, J. C., Ching, A. K., Wong, C. K., Kong, X., Wang, Y., Zhou, L., Chen, Z. and Ng, H. K. (2009) miR-124 is frequently down-regulated in medulloblastoma and is a negative regulator of SLC16A1. *Human pathology*. 40, 1234-1243. <https://doi.org/10.1016/j.humpath.2009.02.003>
20. Silber, J., Hashizume, R., Felix, T., Hariono, S., Yu, M., Berger, M. S., Huse, J. T., VandenBerg, S. R., James, C. D., Hodgson, J. G. and Gupta, N. (2013) Expression of miR-124 inhibits growth of medulloblastoma cells. *Neuro Oncol*. 15, 83-90. <https://doi.org/10.1093/neuonc/nos281>
21. Tenga, A., Beard, J. A., Takwi, A., Wang, Y. M. and Chen, T. (2016) Regulation of Nuclear Receptor Nur77 by miR-124. *PLoS One*. 11, e0148433. <https://doi.org/10.1371/journal.pone.0148433>
22. Zhu, L., Shi, Y., Xiong, Y., Ba, L., Li, Q., Qiu, M., Zou, Z. and Peng, G. (2021) Emerging self-assembling peptide nanomaterial for anti-cancer therapy. *J Biomater Appl*. 36, 882-901. <https://doi.org/10.1177/08853282211027882>
23. Sharma, R., Borah, S. J., Bhawna, Kumar, S., Gupta, A., Singh, P., Goel, V. K., Kumar, R. and Kumar, V. (2022) Functionalized Peptide-Based Nanoparticles for Targeted Cancer Nanotherapeutics: A State-of-the-Art Review. *ACS Omega*. 7, 36092-36107. <https://doi.org/10.1021/acsomega.2c03974>
24. Varshney, A., Panda, J. J., Singh, A. K., Yadav, N., Bihari, C., Biswas, S., Sarin, S. K. and Chauhan, V. S. (2018) Targeted delivery of microRNA-199a-3p using self-assembled dipeptide nanoparticles efficiently reduces hepatocellular carcinoma in mice. *Hepatology*. 67, 1392-1407. <https://doi.org/10.1002/hep.29643>
25. Dai, J., Cheng, Y., Wu, J., Wang, Q., Wang, W., Yang, J., Zhao, Z., Lou, X., Xia, F., Wang, S. and Tang, B. Z. (2020) Modular Peptide Probe for Pre/Intra/Postoperative Therapeutic to Reduce Recurrence in Ovarian Cancer. *ACS Nano*. 14, 14698-14714. <https://doi.org/10.1021/acsnano.9b09818>
26. Li, Q., Cen, B., Huang, W., Chen, J., Chen, Z., Pang, J., Fu, W., He, S. and Ji, A. (2021) [Development and functional validation of a nano-delivery system of miR-16/polypeptide targeting

- ovarian cancer cells]. *Nan fang yi ke da xue xue bao = Journal of Southern Medical University*. 41, 736-746. <https://doi.org/10.12122/j.issn.1673-4254.2021.05.15>
27. Lockhart, J. H., VanWye, J., Banerjee, R., Wickline, S. A., Pan, H. and Totary-Jain, H. (2021) Self-assembled miRNA-switch nanoparticles target denuded regions and prevent restenosis. *Mol Ther*. 29, 1744-1757. <https://doi.org/10.1016/j.ymthe.2021.01.032>
28. Wang, H., Wang, Z., Chen, W., Wang, W., Shi, W., Chen, J., Hang, Y., Song, J., Xiao, X. and Dai, Z. (2021) Self-assembly of photosensitive and radiotherapeutic peptide for combined photodynamic-radio cancer therapy with intracellular delivery of miRNA-139-5p. *Bioorg Med Chem*. 44, 116305. <https://doi.org/10.1016/j.bmc.2021.116305>
29. Fresacher-Scheiber, K., Ruseska, I., Siboni, H., Reiser, M., Falsone, F., Grill, L. and Zimmer, A. (2022) Modified Stability of microRNA-Loaded Nanoparticles. *Pharmaceutics*. 14. <https://doi.org/10.3390/pharmaceutics14091829>
30. Ha, J., Kim, M., Lee, Y. and Lee, M. (2021) Intranasal delivery of self-assembled nanoparticles of therapeutic peptides and antagomirs elicits anti-tumor effects in an intracranial glioblastoma model. *Nanoscale*. 13, 14745-14759. <https://doi.org/10.1039/d1nr03455c>
31. Biswas, S., Yadav, N., Juneja, P., Mourya, A. K., Kaur, S., Tripathi, D. M. and Chauhan, V. S. (2022) Conformationally Restricted Dipeptide-Based Nanoparticles for Delivery of siRNA in Experimental Liver Cirrhosis. *ACS Omega*. 7, 36811-36824. <https://doi.org/10.1021/acsomega.2c05292>
32. Panigrahi, B., Singh, R. K., Suryakant, U., Mishra, S., Potnis, A. A., Jena, A. B., Kerry, R. G., Rajaram, H., Ghosh, S. K. and Mandal, D. (2022) Cyclic peptides nanospheres: A '2-in-1' self-assembled delivery system for targeting nucleus and cytoplasm. *European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences*. 171, 106125. <https://doi.org/10.1016/j.ejps.2022.106125>
33. Wu, L. P., Ahmadvand, D., Su, J., Hall, A., Tan, X., Farhangrazi, Z. S. and Moghimi, S. M. (2019) Crossing the blood-brain-barrier with nanoligand drug carriers self-assembled from a phage display peptide. *Nature communications*. 10, 4635. <https://doi.org/10.1038/s41467-019-12554-2>
34. Liu, J., Guo, N., Gao, C., Liu, N., Zheng, X., Tan, Y., Lei, J., Hao, Y., Chen, L. and Zhang, X. (2019) Effective Gene Silencing Mediated by Polypeptide Nanoparticles LAH4-L1-siMDR1 in Multi-Drug Resistant Human Breast Cancer. *J Biomed Nanotechnol*. 15, 531-543. <https://doi.org/10.1166/jbn.2019.2705>
35. Lin, Y. X., Wang, Y., An, H. W., Qi, B., Wang, J., Wang, L., Shi, J., Mei, L. and Wang, H. (2019) Peptide-Based Autophagic Gene and Cisplatin Co-delivery Systems Enable Improved Chemotherapy Resistance. *Nano Lett*. 19, 2968-2978. <https://doi.org/10.1021/acs.nanolett.9b00083>
36. Vaissiere, A., Aldrian, G., Konate, K., Lindberg, M. F., Jourdan, C., Telmar, A., Seisel, Q., Fernandez, F., Viguier, V., Genevois, C., Couillaud, F., Boisguerin, P. and Deshayes, S. (2017) A retro-inverso cell-penetrating peptide for siRNA delivery. *J Nanobiotechnology*. 15, 34. <https://doi.org/10.1186/s12951-017-0269-2>
37. Zhou, H. F., Yan, H., Pan, H., Hou, K. K., Akk, A., Springer, L. E., Hu, Y., Allen, J. S., Wickline, S. A. and Pham, C. T. (2014) Peptide-siRNA nanocomplexes targeting NF-kappaB subunit p65 suppress nascent experimental arthritis. *J Clin Invest*. 124, 4363-4374. <https://doi.org/10.1172/JCI175673>
38. Liu, L., Liu, X., Xu, Q., Wu, P., Zuo, X., Zhang, J., Deng, H., Wu, Z. and Ji, A. (2014) Self-assembled nanoparticles based on the c(RGDfk) peptide for the delivery of siRNA targeting the VEGFR2 gene for tumor therapy. *International journal of nanomedicine*. 9, 3509-3526. <https://doi.org/10.2147/IJN.S63717>
39. Tagalakis, A. D., Lee, D. H., Bienemann, A. S., Zhou, H., Munye, M. M., Saraiva, L., McCarthy, D., Du, Z., Vink, C. A., Maeshima, R., White, E. A., Gustafsson, K. and Hart, S. L. (2014) Multifunctional, self-assembling anionic peptide-lipid nanocomplexes for targeted siRNA delivery. *Biomaterials*. 35, 8406-8415. <https://doi.org/10.1016/j.biomaterials.2014.06.003>
40. Yin, L., Song, Z., Qu, Q., Kim, K. H., Zheng, N., Yao, C., Chaudhury, I., Tang, H., Gabrielson, N. P., Uckun, F. M. and Cheng, J. (2013) Supramolecular self-assembled nanoparticles mediate oral delivery of therapeutic TNF-alpha siRNA against systemic inflammation. *Angew Chem Int Ed Engl*. 52, 5757-5761. <https://doi.org/10.1002/anie.201209991>
41. Rydstrom, A., Deshayes, S., Konate, K., Crombez, L., Padari, K., Boukhaddaoui, H., Aldrian, G., Pooga, M. and Divita, G. (2011) Direct translocation as major cellular uptake for CADY self-assembling peptide-based nanoparticles. *PLoS One*. 6, e25924. <https://doi.org/10.1371/journal.pone.0025924>
42. Li, S. D., Chen, Y. C., Hackett, M. J. and Huang, L. (2008) Tumor-targeted delivery of siRNA by self-assembled nanoparticles. *Mol Ther*. 16, 163-169. <https://doi.org/10.1038/sj.mt.6300323>
43. Chono, S., Li, S. D., Conwell, C. C. and Huang, L. (2008) An efficient and low immunostimulatory nanoparticle formulation for systemic siRNA delivery to the tumor. *J Control Release*. 131, 64-69. <https://doi.org/10.1016/j.jconrel.2008.07.006>
44. Islam, Y., Khalid, A., Pluchino, S., Sivakumaran, M., Teixido, M., Leach, A., Fatokun, A. A., Downing, J., Coxon, C. and Ehtezazi, T. (2020) Development of Brain Targeting Peptide Based MMP-9 Inhibiting Nanoparticles for the Treatment of Brain Diseases with Elevated MMP-9 Activity. *J Pharm*

- Sci. 109, 3134-3144. <https://doi.org/10.1016/j.xphs.2020.06.021>
45. Islam, Y., Ehtezazi, P., Cashmore, A., Marinsalda, E., Leach, A. G., Coxon, C. R., Fatokun, A. A., Sexton, D. W., Khan, I., Zouganelis, G., Downing, J., Pluchino, S., Sivakumaran, M., Teixido, M. and Ehtezazi, T. (2021) The Inclusion of a Matrix Metalloproteinase-9 Responsive Sequence in Self-assembled Peptide-based Brain-Targeting Nanoparticles Improves the Efficiency of Nanoparticles Crossing the Blood-Brain Barrier at Elevated MMP-9 Levels. *J Pharm Sci.* 110, 1349-1364. <https://doi.org/10.1016/j.xphs.2020.12.004>
46. Milde, T., Lodrini, M., Savelyeva, L., Korshunov, A., Kool, M., Brueckner, L. M., Antunes, A. S., Oehme, I., Pekrun, A., Pfister, S. M., Kulozik, A. E., Witt, O. and Deubzer, H. E. (2012) HD-MB03 is a novel Group 3 medulloblastoma model demonstrating sensitivity to histone deacetylase inhibitor treatment. *Journal of neuro-oncology.* 110, 335-348. <https://doi.org/10.1007/s11060-012-0978-1>
47. Schneider, C. A., Rasband, W. S. and Eliceiri, K. W. (2012) NIH Image to ImageJ: 25 years of image analysis. *Nat Methods.* 9, 671-675. <https://doi.org/10.1038/nmeth.2089>
48. Danaei, M., Dehghankhold, M., Ataei, S., Hasanzadeh Davarani, F., Javanmard, R., Dokhani, A., Khorasani, S. and Mozafari, M. R. (2018) Impact of Particle Size and Polydispersity Index on the Clinical Applications of Lipidic Nanocarrier Systems. *Pharmaceutics.* 10. <https://doi.org/10.3390/pharmaceutics10020057>
49. Ambruosi, A., Yamamoto, H. and Kreuter, J. (2005) Body distribution of polysorbate-80 and doxorubicin-loaded [14C]poly(butyl cyanoacrylate) nanoparticles after i.v. administration in rats. *Journal of drug targeting.* 13, 535-542. <https://doi.org/10.1080/10611860500411043>
50. Jones, S. W., Christison, R., Bundell, K., Voyce, C. J., Brockbank, S. M., Newham, P. and Lindsay, M. A. (2005) Characterisation of cell-penetrating peptide-mediated peptide delivery. *British journal of pharmacology.* 145, 1093-1102. <https://doi.org/10.1038/sj.bjp.0706279>
51. Birch, D., Christensen, M. V., Staerk, D., Franzyk, H. and Nielsen, H. M. (2017) Fluorophore labeling of a cell-penetrating peptide induces differential effects on its cellular distribution and affects cell viability. *Biochim Biophys Acta Biomembr.* 1859, 2483-2494. <https://doi.org/10.1016/j.bbamem.2017.09.015>
52. Biscans, A., Caiazzi, J., Davis, S., McHugh, N., Sousa, J. and Khvorova, A. (2020) The chemical structure and phosphorothioate content of hydrophobically modified siRNAs impact extrahepatic distribution and efficacy. *Nucleic Acids Res.* 48, 7665-7680. <https://doi.org/10.1093/nar/gkaa595>